858 related articles for article (PubMed ID: 29025423)
1. Downregulation of NMI promotes tumor growth and predicts poor prognosis in human lung adenocarcinomas.
Wang J; Zou K; Feng X; Chen M; Li C; Tang R; Xuan Y; Luo M; Chen W; Qiu H; Qin G; Li Y; Zhang C; Xiao B; Kang L; Kang T; Huang W; Yu X; Wu X; Deng W
Mol Cancer; 2017 Oct; 16(1):158. PubMed ID: 29025423
[TBL] [Abstract][Full Text] [Related]
2. Cleavage and polyadenylation specific factor 4 targets NF-κB/cyclooxygenase-2 signaling to promote lung cancer growth and progression.
Yi C; Wang Y; Zhang C; Xuan Y; Zhao S; Liu T; Li W; Liao Y; Feng X; Hao J; Gao Y; Yu W; Chen Y; Zhang C; Guo W; Tang B; Deng W
Cancer Lett; 2016 Oct; 381(1):1-13. PubMed ID: 27450326
[TBL] [Abstract][Full Text] [Related]
3. N-Myc-interacting protein (NMI) negatively regulates epithelial-mesenchymal transition by inhibiting the acetylation of NF-κB/p65.
Hou J; Wang T; Xie Q; Deng W; Yang JY; Zhang SQ; Cai JC
Cancer Lett; 2016 Jun; 376(1):22-33. PubMed ID: 27012186
[TBL] [Abstract][Full Text] [Related]
4. YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma.
Guo T; Zhao S; Wang P; Xue X; Zhang Y; Yang M; Li N; Li Z; Xu L; Jiang L; Zhao L; Ma PC; Rosell R; Li J; Gu C
Oncotarget; 2017 Jul; 8(29):48110-48125. PubMed ID: 28624808
[TBL] [Abstract][Full Text] [Related]
5. YBX1 regulates tumor growth via CDC25a pathway in human lung adenocarcinoma.
Zhao S; Wang Y; Guo T; Yu W; Li J; Tang Z; Yu Z; Zhao L; Zhang Y; Wang Z; Wang P; Li Y; Li F; Sun Z; Xuan Y; Tang R; Deng WG; Guo W; Gu C
Oncotarget; 2016 Dec; 7(50):82139-82157. PubMed ID: 27384875
[TBL] [Abstract][Full Text] [Related]
6. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.
Xiao Y; Wang J; Qin Y; Xuan Y; Jia Y; Hu W; Yu W; Dai M; Li Z; Yi C; Zhao S; Li M; Du S; Cheng W; Xiao X; Chen Y; Wu T; Meng S; Yuan Y; Liu Q; Huang W; Guo W; Wang S; Deng W
Oncotarget; 2015 Apr; 6(10):8046-61. PubMed ID: 25797267
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
[TBL] [Abstract][Full Text] [Related]
8. MnSOD promotes tumor invasion via upregulation of FoxM1-MMP2 axis and related with poor survival and relapse in lung adenocarcinomas.
Chen PM; Wu TC; Shieh SH; Wu YH; Li MC; Sheu GT; Cheng YW; Chen CY; Lee H
Mol Cancer Res; 2013 Mar; 11(3):261-71. PubMed ID: 23271813
[TBL] [Abstract][Full Text] [Related]
9. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
[TBL] [Abstract][Full Text] [Related]
10. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas.
Niki T; Kohno T; Iba S; Moriya Y; Takahashi Y; Saito M; Maeshima A; Yamada T; Matsuno Y; Fukayama M; Yokota J; Hirohashi S
Am J Pathol; 2002 Mar; 160(3):1129-41. PubMed ID: 11891209
[TBL] [Abstract][Full Text] [Related]
11. GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing Wnt/β-catenin signaling in lung adenocarcinoma.
Yuan S; Yu Z; Liu Q; Zhang M; Xiang Y; Wu N; Wu L; Hu Z; Xu B; Cai T; Ma X; Zhang Y; Liao C; Wang L; Yang P; Bai L; Li Y
Oncogene; 2016 Nov; 35(47):6120-6131. PubMed ID: 27157618
[TBL] [Abstract][Full Text] [Related]
12. hnRNPA2/B1 activates cyclooxygenase-2 and promotes tumor growth in human lung cancers.
Xuan Y; Wang J; Ban L; Lu JJ; Yi C; Li Z; Yu W; Li M; Xu T; Yang W; Tang Z; Tang R; Xiao X; Meng S; Chen Y; Liu Q; Huang W; Guo W; Cui X; Deng W
Mol Oncol; 2016 Apr; 10(4):610-24. PubMed ID: 26774881
[TBL] [Abstract][Full Text] [Related]
13. Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades.
Wang X; Yu Z; Wang C; Cheng W; Tian X; Huo X; Wang Y; Sun C; Feng L; Xing J; Lan Y; Sun D; Hou Q; Zhang B; Ma X; Zhang B
J Exp Clin Cancer Res; 2017 Jul; 36(1):93. PubMed ID: 28701209
[TBL] [Abstract][Full Text] [Related]
14. Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.
Zhou X; Li D; Wang X; Zhang B; Zhu H; Zhao J
Oncotarget; 2015 Feb; 6(5):3111-22. PubMed ID: 25605013
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells.
Wang J; Xiao X; Zhang Y; Shi D; Chen W; Fu L; Liu L; Xie F; Kang T; Huang W; Deng W
J Pineal Res; 2012 Aug; 53(1):77-90. PubMed ID: 22335196
[TBL] [Abstract][Full Text] [Related]
16. Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.
Lu JJ; Fu L; Tang Z; Zhang C; Qin L; Wang J; Yu Z; Shi D; Xiao X; Xie F; Huang W; Deng W
Oncotarget; 2016 Jan; 7(3):2985-3001. PubMed ID: 26672764
[TBL] [Abstract][Full Text] [Related]
17. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
18. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas.
Tsai LH; Chen PM; Cheng YW; Chen CY; Sheu GT; Wu TC; Lee H
Oncogene; 2014 Jul; 33(29):3851-60. PubMed ID: 23995788
[TBL] [Abstract][Full Text] [Related]
19. Rig-G is a growth inhibitory factor of lung cancer cells that suppresses STAT3 and NF-κB.
Li D; Sun J; Liu W; Wang X; Bals R; Wu J; Quan W; Yao Y; Zhang Y; Zhou H; Wu K
Oncotarget; 2016 Oct; 7(40):66032-66050. PubMed ID: 27602766
[TBL] [Abstract][Full Text] [Related]
20. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
